OncoMatch/Clinical Trials/NCT03922724
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Is NCT03922724 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for peripheral t-cell lymphomas.
Treatment: ATL-RIC · mRIC · RIC · GVHD prophylaxis · IOC — Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of getting a recipient ready for a transplant may result in fewer problems and side effects. Eligibility: Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to standard treatments Donors: Healthy people ages 18 and older whose relative has lymphoma Design: Participants will be screened with: Physical exam Blood and urine tests Bone marrow biopsy: A needle inserted into the participant s hip bone will remove marrow. Donors will also be screened with: X-rays Recipients will also be screened with: Lying in scanners that take pictures of the body Tumor sample Donors may donate blood. They will take daily shots for 5 7 days. They will have apheresis: A machine will take blood from one arm and take out their stem cells. The blood will be returned into the other arm. Recipients will be hospitalized at least 2 weeks before transplant. They will get a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy. Recipients will get the transplant through their catheter. Recipients will stay in the hospital several weeks after transplant. They will get blood transfusions. They will take drugs including chemotherapy for about 2 months. Recipients will have visits 6, 12, 18, 24 months after transplant, then once a year for 5 years.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
Estimated creatinine clearance >= 50 mL/min/1.73 m^2, calculated using eGFR for adults and Schwartz formula for pediatrics
Liver function
Bilirubin <= 3.0 mg/dL (RIC) or <= 5.0 mg/dL (IOC) unless due to Gilbert's syndrome or hemolysis; ALT and AST <= 10 x ULN (RIC or IOC); patients above thresholds may be eligible if hepatologist deems abnormalities disease related
Cardiac function
For RIC: LVEF >= 40% by ECHO or MUGA, left ventricular shortening fraction >= 20% by ECHO, or LVEF >= 30% if radiologic evidence of vasculitis; For IOC: LVEF >= 30% by ECHO or MUGA
Adequate end-organ function, as measured by: ... Bilirubin <= 3.0 mg/dL (RIC) or <= 5.0 mg/dL (IOC) ... ALT and AST <= 10 x ULN ... Estimated creatinine clearance >= 50 mL/min/1.73 m^2 ... LVEF >= 40% (RIC) or >= 30% (IOC) ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
- National Marrow Donor Program · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify